SCRIPT BIOSCIENCES INC

Biotech · Defunct

Platform technology that improves accuracy and safety of gene editing by reducing off-target effects and unintended insertions

Grants
$274K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: CasPlus: A safer, more efficient, and targeted method of deploying CRISPR in vivo$274,438
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1839TRANSLATIONAL SCIENCES INC.——
1840Entelo, Inc.—$4.9M
1841KDAc Therapeutics, Inc.——
1842SCRIPT BIOSCIENCES INC——
1843HCO ANTIBODY, INC.——
1844MARIPOSA HOLDINGS GROUP, INC.—$280K
1845Javelin Oncology, Inc.—$1.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Compositions And Methods For Targeted Modification Of MSH3application
  • Compositions And Methods For Targeted Modification Of MSH3application
  • Compositions And Methods For Targeted Modification Of MSH3application

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.